This study focuses on adults with Multifocal Motor Neuropathy, a rare neurological condition that affects motor nerves and causes progressive muscle weakness. The research compares two treatments: a new medication called empasiprubart and standard therapy with intravenous immunoglobulin (a treatment made from donated blood plasma that contains antibodies). The study will also use placebo solutions for comparison purposes.
The main purpose of this research is to determine if empasiprubart is effective at improving muscle strength compared to intravenous immunoglobulin in people with Multifocal Motor Neuropathy. Both medications will be given through intravenous infusion, which means they are administered directly into a vein.
The study is divided into two parts. During the treatment period, participants will receive either empasiprubart or intravenous immunoglobulin along with their matching placebos. Throughout the study, doctors will measure changes in muscle strength and other aspects of the condition. The research team will also monitor the safety of the treatments and collect information about how well participants feel and function in their daily activities.
Austria 
Belgium 
Czechia 
Denmark 
Estonia 
France 
Germany 
Greece 
Italy 
Latvia 
Lithuania 
Norway 
Poland 
Portugal 
Slovakia 
Slovenia 
Spain 
Sweden 
The Netherlands